|
||
Ciprofloxabol Pregnancy |
||
Contraindicated in pregnancy (safety and efficacy in women during pregnancy has not been established); Ciprofloxabol crosses the placenta, excreted in breast milk.
In experimental studies found that it causes arthropathy. In experiments on rats and mice treated with Ciprofloxabol in doses exceeding the usual daily dose for a person 6 times, adverse effects on the fetus is not revealed. In experiments on rabbits treated with oral dose of Ciprofloxabol 30 and 100 mg / kg, it is shown that the drug causes disruption of the gastrointestinal tract, leading to loss of body weight in females and increase the number of miscarriages but teratogenicity not found. When IV introduction to the doses of 20 mg / kg Ciprofloxabol did not exert toxic effects on the mother and embryo, showed no teratogenicity. The use of local forms of Ciprofloxabol in pregnancy is possible if the anticipated benefits exceed the potential risk to the fetus.
Category of the fetus by FDA - C.
Ciprofloxabol is excreted in breast milk, so the period of lactation should decide, stop taking Ciprofloxabol or breastfeeding based on the degree of importance of the use of drugs for the mother.
With careful use of local forms of Ciprofloxabol in breast-feeding (not known whether Ciprofloxabol is excreted in breast milk when applied topically).
There are no data on the excretion of Ciprofloxabol otic into human milk. Concentrations of orally administered Ciprofloxabol found in breast milk have ranged from 85% (at 24 hours post dose) to 214% (at 4 hours post dose) of maternal serum concentration. In one case report, an infant developed perforated pseudomembranous colitis following ingestion of Ciprofloxabol via the mother's milk. In addition, quinolone-induced cartilage erosion and arthropathies that have been observed in juvenile animals render some concern over its possible toxic effects on the developing joints of nursing infants. However, limited data indicate that systemic absorption after otic administration is extremely low. Plasma levels of Ciprofloxabol and hydrocortisone are expected to be below the level of quantitation after administration of 3 drops of suspension into the ear. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue the drug or to discontinue nursing, taking into account the importance of the drug to the mother.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|